biostudies-literatureJoly FAstraZeneca7950https://www.ebi.ac.uk/biostudies/studies/S-EPMC12381027biostudies-literatureUnknown16(1)Single-agent maintenance poly(ADP-ribose) polymerase (PARP) inhibition may represent an effective strategy in patients with advanced/metastatic endometrial cancer responding to platinum-based chemotherapy, including for molecular subtypes with suboptimal options. To explore this approach, we initiated the randomized phase IIb UTOLA trial (NCT03745950). Female patients without progression following front-line platinum-based chemotherapy for advanced/metastatic endometrial cancer were randomized 2:1 to twice-daily maintenance oral olaparib 300 mg or placebo until progression or intolerance, stratified by p53 status, mismatch repair status, and response to initial chemotherapy. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. Secondary endpoints wNature communicationsMaintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.PMC12381027N/AKaczmarek EArnaud AHardy Bessard ACRodrigues MJoly FAsselain BBonnet EJeanne CCojean-Zelek IGladieff LRoche SMeunier JBengrine Lefevre LFabbro MFernandez Diez YLeroy KCallens CFournel PLargillier RFrenel JSAbadie-Lacourtoisie SLebreton CRay-Coquard ILeary AMeynard GLeman RFollana PFoa CAlexandre JJust PASelle FYou BfalseMaintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.Single-agent maintenance poly(ADP-ribose) polymerase (PARP) inhibition may represent an effective strategy in patients with advanced/metastatic endometrial cancer responding to platinum-based chemotherapy, including for molecular subtypes with suboptimal options. To explore this approach, we initiated the randomized phase IIb UTOLA trial (NCT03745950). Female patients without progression following front-line platinum-based chemotherapy for advanced/metastatic endometrial cancer were randomized 2:1 to twice-daily maintenance oral olaparib 300 mg or placebo until progression or intolerance, stratified by p53 status, mismatch repair status, and response to initial chemotherapy. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. Secondary endpoints w2025-01-01T00:00:00Z2025 Aug2026-05-29T19:29:57.104Z2026-04-08T05:44:39.502ZS-EPMC123810274085855810.1038/s41467-025-62678-x